Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic

M Betti1, R Voltan, M Marchisio

  • 1Department of Experimental and Diagnostic Medicine, University of Ferrara, Via Luigi Borsari 46, 44100, Ferrara, Italy.

Vaccine
|May 12, 2001
PubMed

Previous work from our group showed that genetic immunization of mice with HIV-1 tat genes (tat22 and tat22/37), encoding Tat proteins mutated in the transactivation domain and lacking Tat-transactivating activity, evoke an immune response to wild-type Tat, both humoral and cellular. In the present work we report that the mutated Tat proteins localize within the cells, are released and taken up by the cells in a fashion similar to wild-type Tat. Moreover, the exogenous mutated Tat proteins interfere with the transactivating function of extracellular wild-type Tat. These results support the notion that tat22 and tat22/37 genes may represent good candidates for the development of an anti-HIV-1 vaccine, especially for HIV-1 infected patients.